Factors Associated With a Patient’s Decision to Select a Cost-effective vs the Most Effective Therapy for Their Own Eye Disease

IMPORTANCE: Ten percent of the Medicare Part B budget is spent on aflibercept, used to treat a myriad of ocular neovascular diseases. A substantial portion of these costs can be attributed to a few hundred ophthalmologists, raising concerns regarding the influence of pharmaceutical companies on the...

Descripción completa

Detalles Bibliográficos
Autores principales: Malik, Danyal, Cao, Xuan, Sanchez, Jaron Castillo, Gao, Tianshun, Qian, Jiang, Montaner, Silvia, Sodhi, Akrit
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2021
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7900858/
https://www.ncbi.nlm.nih.gov/pubmed/33616665
http://dx.doi.org/10.1001/jamanetworkopen.2020.37880

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7900858/
https://www.ncbi.nlm.nih.gov/pubmed/33616665
http://dx.doi.org/10.1001/jamanetworkopen.2020.37880

Ejemplares similares